Talem Therapeutics and Pierre Fabre to form antibody research collaboration

pharmafile | October 8, 2021 | News story | Medical Communications  

Talem Therapeutics, subsidiary of Immunoprecise Antibodies Ltd (IPA), and the Pierre Fabre pharmaceutical group have announced a multi-target research collaboration, to discover and develop therapeutics antibodies for up to nine targets.

This strategic partnership will expand Talem’s portfolio of novel antibodies across oncology, and it adds to the relationships that the IPA group have cultivated across the pharmaceutical and biotechnology sector.

Pierre Fabre is the second largest dermo-cosmetics laboratory in the world, and is the market leader in France for over-the-counter products sold in pharmacies. The company has cemented their expertise over the last 35 years since their foundation, with considerable experience in oncology covering innovation, development, manufacturing, and commercialisation.

Talem Therapeutics is focused on the discovery and development of next-generation, human, monoclonal, therapeutic antibodies. Talem builds on the antibody discovery platforms and innovation technologies at IPA, to accelerate novel antibody treatments alongisde strategic partners.

The antibodies developed in the research collaboration will be jointly owned by Talem and Fabre.

Dr Stefan Lang, Chief Business Officer of ImmunoPrecise, commented, “Less than two years ago we started Talem Therapeutics to provide a unique partnering opportunity for companies to jointly seek the development of promising novel candidates.

“We are very excited to join forces with Pierre Fabre, combining our advanced antibody technologies with their world-class expertise in immuno-oncology is a powerful strategic combination enabling the teams to jointly address life threatening human diseases.”

“Drug discovery in immuno-oncology is a priority for Pierre Fabre. We are therefore very pleased to enter this multi-target research collaboration. Talem will provide us with its expertise and a variety of technology platforms to enable the discovery of therapeutic antibodies, towards a set of structurally diverse targets,” said Francesco Hofmann, Head of R&D at Pierre Fabre Medical Care. 

Lina Adams


Related Content

No items found

Latest content